$PFE (Pfizer Inc.)

$PFE {{ '2015-12-07T18:53:18+0000' | timeago}} • Announcement

Pharmaceutical company $PFE said that it has received U.S. FDA approval for QuilliChew ER (methylphenidate hydrochloride) extended-release chewable tablets, treatment for ADHD in patients ages 6 years old and above.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$PFE {{ '2017-07-13T12:13:49+0000' | timeago}} • Announcement

The FDA has accepted $PFE's filing of supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis. The FDA has provided an anticipated Prescription Drug User Fee Act action date in March 2018 for the sNDA.

$PFE {{ '2017-07-12T11:41:14+0000' | timeago}} • Announcement

$PFE said the FDA's Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk benefit profile for Mylotarg on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

$PFE {{ '2017-07-11T20:58:23+0000' | timeago}} • Announcement

The US FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of $PFE's MYLOTARG (gemtuzumab ozogamicin), an antibody-drug conjugate used to treat acute myeloid leukemia. The role of the ODAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve MYLOTARG is anticipated by Sept. 2017.

$PFE {{ '2017-06-30T12:36:12+0000' | timeago}} • Announcement

$PFE received approval for its Besponsa as monotherapy from the European Commission. The Besponsa was approved for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). ALL is an aggressive type of leukemia that can be fatal within a matter of months if left untreated.

$PFE {{ '2017-06-27T13:34:31+0000' | timeago}} • Announcement

$PFE broke ground on its new R&D and process development facility in Chesterfield, Missouri. Construction is expected to be complete by mid-2019. The facility will house more than 450 employees who currently work at multiple locations, and an additional 80 employees that the company expects to hire over the coming years.

$PFE {{ '2017-06-22T20:52:12+0000' | timeago}} • Announcement

$PFE declared a $0.32 3Q17 dividend on the company’s common stock, payable September 1, 2017, to shareholders of record as on August 4, 2017.

$ACET {{ '2017-06-20T14:58:15+0000' | timeago}} • Announcement

$ACET said its finished dosage form generics subsidiary Rising Pharmaceuticals has launched Glipizide Extended Release Tablets, an FDA-approved generic version of the reference listed drug, Glucotrol XL from $PFE. Glipizide are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

$PFE {{ '2017-06-19T13:59:58+0000' | timeago}} • Announcement

$PFE started a Phase 1 trial in healthy volunteers of PF-06760805, an investigational vaccine designed to help protect against Group B Streptococcus (GBS) infection. In newborns, GBS manifests as sepsis, pneumonia, and meningitis, with potentially fatal outcomes for some, and long-lasting neurological damage in 46-50% of those infected.

$PFE {{ '2017-06-16T11:38:06+0000' | timeago}} • Announcement

Pharma company $PFE said its phase-3b/4 study of Xeljanz, a drug indicted for the treatment of moderate to severe rheumatoid arthritis, showed it provided a response rate that is similar to Humira, which is used in the treatment of moderate to severe rheumatoid arthritis in combination with methotrexate.

$PFE {{ '2017-06-13T15:05:11+0000' | timeago}} • Announcement

Pharma firms $PFE and $LLY have received fast track designation from the FDA for tanezumab, an antibody against nerve growth factor. If approved, Tanezumab would be the first in the new class of non-opioid chronic medications. Meanwhile, results of an ongoing phase-3 clinical development program for tanezumab are projected to start coming in 2018.

$PFE {{ '2017-06-13T14:51:52+0000' | timeago}} • Announcement

$PFE and $LLY said that the FDA has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF).

$MRK {{ '2017-06-12T11:25:01+0000' | timeago}} • Announcement

$MRK, in partnership with $PFE, announced that two Phase 3 studies of ertugliflozin, an investigational oral drug to help improve glucose level control in adults with type 2 diabetes, met their primary endpoints.

$PFE {{ '2017-06-06T15:45:09+0000' | timeago}} • Announcement

$PFE announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to tafamidis, the company’s investigational treatment for transthyretin cardiomyopathy, a rare disease associated with progressive heart failure.

$PFE {{ '2017-06-05T11:50:02+0000' | timeago}} • Announcement

$PFE announced Phase 2 data showing that its investigational, dual-mechanism poly ADP ribose polymerase inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline (inherited) BRCA1/2-positive advanced breast cancer.

$PFE {{ '2017-05-30T20:06:33+0000' | timeago}} • Announcement

$PFE said European Commission (EC) has approved Trumenba (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. It can cause severe brain damage and is fatal in 50% of cases if untreated.

$PFE {{ '2017-05-24T12:27:07+0000' | timeago}} • Announcement

$PFE received notice of an unsolicited mini-tender offer by TRC Capital Corp, of Ontario, Canada to buy up to 4MM shares of $PFE common stock at a price of $31.60 per share in cash. $PFE recommends stockholders not to tender their shares in response to TRC Capital's offer because the offer is at a price below the current market price.

$SGMO {{ '2017-05-11T12:04:01+0000' | timeago}} • Announcement

$SGMO said it is eligible to receive potential milestone payments of up to $475MM, including up to $300MM for the development and commercialization of SB-525 and up to $175MM for additional Hemophilia A gene therapy product candidates that may be developed under the collaboration with $PFE.

$SGMO {{ '2017-05-11T12:03:12+0000' | timeago}} • Announcement

$SGMO said it will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. $PFE will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525 and additional products, if any.

$SGMO {{ '2017-05-11T12:02:25+0000' | timeago}} • Announcement

$SGMO and $PFE announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of $SGMO's four lead product candidates, which $SGMO expects will enter the clinic this quarter. $SGMO will receive a $70MM upfront payment from $PFE.

Recent Transcripts

MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
VCEL (Vericel Corporation)
Wednesday, May 10 2017 - 12:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
VCEL (Vericel Corporation)
Friday, March 10 2017 - 1:00pm
ARQL (ArQule Inc.)
Tuesday, March 7 2017 - 2:00pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, February 23 2017 - 9:30pm
ZTS (Zoetis Inc.)
Thursday, February 16 2017 - 1:30pm

AlphaGraphics you may like